Valuation in Life Sciences A Practical Guide /

Capital, whether it originates from venture, public equity, private, or g- ernment sources, continues to be biotech’s source of sustenance. In fact, access to financing can make or break a company, regardless of whether it has Nobel Prize winning science or a top-flight business school mana- ment te...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Bogdan, Boris (Συγγραφέας), Villiger, Ralph (Συγγραφέας)
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Berlin, Heidelberg : Springer Berlin Heidelberg, 2007.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 03488nam a22005415i 4500
001 978-3-540-45567-7
003 DE-He213
005 20151204141345.0
007 cr nn 008mamaa
008 100301s2007 gw | s |||| 0|eng d
020 |a 9783540455677  |9 978-3-540-45567-7 
024 7 |a 10.1007/978-3-540-45567-7  |2 doi 
040 |d GrThAP 
050 4 |a HG1-HG9999 
072 7 |a KFF  |2 bicssc 
072 7 |a BUS027000  |2 bisacsh 
082 0 4 |a 332  |2 23 
100 1 |a Bogdan, Boris.  |e author. 
245 1 0 |a Valuation in Life Sciences  |h [electronic resource] :  |b A Practical Guide /  |c by Boris Bogdan, Ralph Villiger. 
264 1 |a Berlin, Heidelberg :  |b Springer Berlin Heidelberg,  |c 2007. 
300 |a XII, 249 p. 94 illus.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
505 0 |a Introduction -- Fundamentals in Life Sciences -- Basics of Valuation -- Project Valuation -- License Contract Valuation -- Technology Valuation -- IP Valuation -- Firm Valuation -- Advanced Topics -- Valuation and Gut Feeling -- Excercises. 
520 |a Capital, whether it originates from venture, public equity, private, or g- ernment sources, continues to be biotech’s source of sustenance. In fact, access to financing can make or break a company, regardless of whether it has Nobel Prize winning science or a top-flight business school mana- ment team. In order to attract capital there has to be a “value proposition” that is sufficiently engaging and well constructed that will not only capture the imagination of investors but also make them want to ultimately invest. This book recognizes that there is no consent on how to apply valuation methodologies in life sciences. One of the complicating factors is that, compared to other industries, valuation of biotech innovation is much more demanding. The long 10-15-year development and clinical trials process still represents the main risks faced by any biotech company. Added to that is the fact that getting a drug across the regulatory goal line and receiving Food and Drug Administration approval (or other regulatory agency - proval in the United States or elsewhere in the world) for marketing is no longer good enough. Since the biotechnology industry is not isolated from the major influences affecting the overall healthcare industry, the reality of de facto healthcare cost controls will mean a significant reduction in “peak sales” for individual drugs. Science will no longer be the deciding factor; payor agents will play a far more activist role via reimbursement criteria, co-payment arrangements and similar rationing technologies. 
650 0 |a Finance. 
650 0 |a Pharmacy. 
650 0 |a Management. 
650 0 |a Biotechnology. 
650 0 |a Health informatics. 
650 0 |a Bioinformatics. 
650 0 |a Computational biology. 
650 1 4 |a Finance. 
650 2 4 |a Finance, general. 
650 2 4 |a Computer Appl. in Life Sciences. 
650 2 4 |a Health Informatics. 
650 2 4 |a Pharmacy. 
650 2 4 |a Biotechnology. 
650 2 4 |a Management. 
700 1 |a Villiger, Ralph.  |e author. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783540455653 
856 4 0 |u http://dx.doi.org/10.1007/978-3-540-45567-7  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBE 
950 |a Business and Economics (Springer-11643)